Clinical trial NCT00048659: YM598 Added to Mitoxantrone/Prednisone to Control Pain in Metastatic Prostate Cancer Patients No Longer Responding to Hormone Therapy
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Hormone-Refractory Prostate Cancer
Prostatic Neoplasms
Keywords: Androgen-independent prostate cancer
Lead sponsor: Astellas Pharma Inc
Sponsor class: INDUSTRY
Collaborators: name: Astellas Pharma US, Inc.
First posted: 2002-11-06
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine if patients who take YM598 in addition to mitoxantrone and prednisone (standard therapy) experience improvement in the pain associated with prostate cancer metastases in the bone.



Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Anchorage
country: United States
facility: Alaska Clinical Research Center, LLC
state: Alaska
city: San Bernardino
country: United States
facility: San Bernardino Urological Associates
state: California
city: Torrance
country: United States
facility: Western Clinical Research, Inc.
state: California
city: Gainesville
country: United States
facility: Shands Hospital
state: Florida
city: Miami
country: United States
facility: Sylvester Comprehensive Cancer Center
state: Florida
city: Atlanta
country: United States
facility: Georgia Urology,PA Research Institute
state: Georgia
city: Chicago
country: United States
facility: University of Chicago, Section of Hematology/Oncology
state: Illinois
city: Chicago
country: United States
facility: University of Illinois, Department of Urology
state: Illinois
city: South Bend
country: United States
facility: Michiana Hematology/Oncology
state: Indiana
city: Gretna
country: United States
facility: The Urologic Institute of New Orleans
state: Louisiana
city: Detroit
country: United States
facility: Henry Ford Hospital
state: Michigan
city: St. Louis
country: United States
facility: Washington University School of Medicine
state: Missouri
city: Memphis
country: United States
facility: Memphis Cancer Center
state: Tennessee
city: Seattle
country: United States
facility: Virginia Mason Medical Center
state: Washington
city: Canberra
country: Australia
facility: Department of Medical Oncology, The Canberra Hospital
city: Concord
country: Australia
facility: Department of Medical Oncology, Concord Hospital Medical Centre
city: Herston
country: Australia
facility: Division of Oncology Ward, Royal Brisbane Hospital
city: St Leonards
country: Australia
facility: Department of Clinical Oncology, Royal North Shore Hospital
city: Sydney
country: Australia
facility: Cancer Care Centre, St. George Hospital
city: Waratah
country: Australia
facility: Department of Medical Oncology, Newcastle Mater Hospital
city: Wollongong
country: Australia
facility: Southern Medical Day Care Centre
city: Woodville
country: Australia
facility: Queen Elizabeth Hospital, Clinical Hematology & Oncology
city: Bruxelles
country: Belgium
facility: Cliniques Universitaires St-Luc, Service d'Urologie
city: Charleroi
country: Belgium
facility: Centre Hospitalier Notre Dame et Reine Fabiola, Service d'oncologie
city: Angers
country: France
facility: Centre Paul Papin
city: Creteil
country: France
facility: Service d'Urologie, Hôpital Henri Mondor
city: Lyon
country: France
facility: Pavillon V, Service d'Urologie et de transplatation, Hôpital Edouard Herriot
city: Paris
country: France
facility: Service d' Urologie CHU, Hopital Bichat
city: Berlin
country: Germany
facility: Krankenhause am Urban, Urologie Dieffenfachstr
city: Essen
country: Germany
facility: Dept Urology University of Essen
city: Hannover
country: Germany
facility: Urologische Klinik der MHH
city: Mannheim
country: Germany
facility: Klinikum Mannheim Urology
city: Dublin
country: Ireland
facility: Mater Misericordiae Hospital
city: Utrecht
country: Netherlands
facility: Universitair Medisch Centrum Utrecht, Dienst Medische Oncologie
city: Krakow
country: Poland
facility: Kilinika Chemioterapii, Centrum Onkologii Instytut im M sklodowskiej Curie
city: Krakow
country: Poland
facility: Oddzial Chemioterapii
city: Lodz
country: Poland
facility: Klinika Chemioterapii AM
city: Opole
country: Poland
facility: Samodzielny Publiczny Zaklad Opieki zdrowotnej, Wojewodzki Osrodek Onkologii
city: Tarnow
country: Poland
facility: Szpital Wojewodzki im Sw Lukasza SP ZOZ Tarnow
city: Warsaw
country: Poland
facility: Szpital CSK WAMl, Klinika Okologii
city: Warszawa
country: Poland
facility: Klinika Nowotworow Ukladu
city: Barcelona
country: Spain
facility: Hospital Clinic i Provincial, Servicio de Oncologia
city: Barcelona
country: Spain
facility: Hospital General Vall d'Hebron, Servicio de Oncología
city: Getafe (Madrid)
country: Spain
facility: Hospital Universitario de Getafe, Servicio de Urologia, Crta
city: Madrid
country: Spain
facility: Hospital Universitario Príncipe de Asturias, Servicio de Urología
city: Valencia
country: Spain
facility: Instituto Valenciano de Oncologia, Servicio de Oncologia
city: Devon
country: United Kingdom
facility: Department of Urological Research, Derriford Hospital
city: London
country: United Kingdom
facility: Clinical Research Centre, St George's Hospital, Urology Division
city: London
country: United Kingdom
facility: Department of Urology, St Bartholomew's Hospital
city: London
country: United Kingdom
facility: Imperial College School of Medicine, Dept Cancer Medicine
city: Surrey
country: United Kingdom
facility: Department of Urology, East Surrey Hospital
city: Surrey
country: United Kingdom
facility: Royal Surrey County Hospital
city: West Sussex
country: United Kingdom
facility: St Richard's Hospital
Study officials:
References: